Abstract Objective This study aims to explore the relationship between the Triglyceride Glucose Body Mass Index (TyG-BMI) and the risk of developing benign prostatic hyperplasia (BPH). Methods Utilizing data from the China Health and Ret…
Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…
Abstract Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF a…
OBJECTIVE: To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia. METHODS: A cohort of 58 PMF patients with anemia …
OBJECTIVE: To identify the differential expressed proteins, and to investigate the relationship between altered expression of annexin A4 during window of implantation [WOI (at day-6 after ovulatory day)] in infertile patients with endometri…